Engineered bacterial extracellular vesicles for osteoporosis therapy

Liu, Han; Li, Mengmeng; Zhang, Tao; Liu, Xinru; Zhang, Hao; Zhang, Geng; Su, Jiacan

doi:10.1016/j.cej.2022.138309

Cited by 28 publications

(15 citation statements)

References 143 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The EVs produced by osteogenic differentiation of BMSCs play an important regulatory role in the osteogenic differentiation through their specific miRNAs 17 . However, natural EVs have low miRNA content and can play a limited regulatory role 18 . Engineering EVs can improve their therapeutic efficiency.…”

Section: Evsmentioning

confidence: 99%

Organoid and organoid extracellular vesicles for osteoporotic fractures therapy: Current status and future perspectives

Liu

2023

Interdisciplinary Medicine

Self Cite

View full text Add to dashboard Cite

Osteoporosis is a systemic and degenerative disease characterized by low bone mass and fragile microarchitecture, which predispose patients to fragility fractures, also known as osteoporotic fractures (OPF). OPF have become a major social problem that threaten the health of the elderly. Over the past decade, organoids and organoids extracellular vesicles (OEVs) play a significant role in OPF repair. Organoids have been widely used for fractures treatment. Moreover, EVs are promising nanocarriers due to their cell‐free system, stable drug loading capacity, nanometer size, and good biocompatibility. Importanly, compared with traditional EVs, OEVs have more quantity, better physiological effects, and better therapeutic effects. Therefore, the development of organoid and OEVs in the treatment of OPF is of great significance. Here, we summarize the current status and future perspectives of organoids and OEVs, which will provide innovative solutions to OPF repair.

show abstract

Section: Evsmentioning

confidence: 99%

Organoid and organoid extracellular vesicles for osteoporotic fractures therapy: Current status and future perspectives

Liu

2023

Interdisciplinary Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…86 To address these issues, there has been increasing interest in modifying, engineering, or designing BEVs to enhance their efficiency, specificity, and safety. 87 Engineered BEVs have emerged as a promising alternative approach for EV-based therapy.…”

Section: Engineered Bevsmentioning

confidence: 99%

“…Different production and isolation techniques can cause significant heterogeneity, which hamper the reproducibility and repeatability of results. 87 Despite the ongoing challenges, continued research on engineered BEVs will eventually yield innovative solutions for clinical translation.…”

Section: Engineered Bevsmentioning

confidence: 99%

Bacterial extracellular vesicles: A position paper by the microbial vesicles task force of the Chinese society for extracellular vesicles

Wen

Wang

et al. 2023

Interdisciplinary Medicine

Self Cite

View full text Add to dashboard Cite

Recently, the interest in extracellular vesicles released by bacteria has rapidly increased. Bacterial extracellular vesicles (BEVs) have been involved in bacteria‐bacteria and bacteria‐host interactions, which strengthen health or bring about various pathologies. However, BEV separation, characterization, and functional studies require the establishment of guidelines and further optimization in order to stimulate the development of science in BEV research and a following successful transformation into clinical applications. This position paper is authored by the Microbial Vesicles Task Force of the Chinese Society for Extracellular Vesicles (CSEV) composed of experienced medical laboratory specialists, microbiologists, virologists, biologists and material biologists who are actively engaged in BEV research. Herein, we present a concise description of BEV research and discover challenges and critical gaps in current BEV‐based analyses for clinical applications. Finally, we also offer suggestions and considerations to improve experimental reproducibility and interoperability in BEV research to promote progress in the field.

show abstract

“…However, further studies are required for clarification. Additional sources of EVs that have been described include amniotic and embryonically derived EVs [107][108][109] . These sources of EVs are not as well described as BMMSC-EVs or ADMSC-EVs.…”

Section: Molecular Composition and Cell Sources Of Evsmentioning

confidence: 99%

“…These sources of EVs are not as well described as BMMSC-EVs or ADMSC-EVs. However, there is increasing evidence showing they play an important role in maternal cross-talk and immunomodulation and also possess potent anti-inflammatory properties that are similar to their parent MSC [107][108][109] . Bacterial EVs are also naturally occurring and have been investigated for treating bone disease (i.e., osteoporosis) [110,111] .…”

Section: Molecular Composition and Cell Sources Of Evsmentioning

confidence: 99%

Extracellular vesicles in the treatment and prevention of osteoarthritis: can horses help us translate this therapy to humans?

O’Brien¹,

Hollinshead²,

Goodrich³

2023

Extracell Vesicles Circ Nucleic Acids

View full text Add to dashboard Cite

Osteoarthritis (OA) is a common joint disease affecting humans and horses, resulting in significant morbidity, financial expense, and loss of athletic use. While the pathogenesis is incompletely understood, inflammation is considered crucial in the development and progression of the disease. Mesenchymal stromal cells (MSCs) have received increasing scientific attention for their anti-inflammatory, immunomodulatory, and pro-regenerative effects. However, there are concerns about their ability to become a commercially available therapeutic. Extracellular vesicles (EVs) are now recognized to play a crucial role in the therapeutic efficacy observed with MSCs and offer a potentially novel cell-free therapeutic that may negate many of the concerns with MSCs. There is evidence that EVs have profound anti-inflammatory, immunomodulatory, and pro-regenerative effects equal to or greater than the MSCs they are derived from in the treatment of OA. Most of these studies are in small animal models, limiting the translation of these results to humans. However, highly translational animal models are crucial for further understanding the efficacy of potential therapeutics and for close comparisons with humans. For this reason, the horse, which experiences the same gravitational impacts on joints similar to people, is a highly relevant large animal species for testing. The equine species has well-designed and validated OA models, and additionally, therapies can be further tested in naturally occurring OA to validate preclinical model testing. Therefore, the horse is a highly suitable model to increase our knowledge of the therapeutic potential of EVs.

show abstract

Engineered bacterial extracellular vesicles for osteoporosis therapy

Cited by 28 publications

References 143 publications

Organoid and organoid extracellular vesicles for osteoporotic fractures therapy: Current status and future perspectives

Organoid and organoid extracellular vesicles for osteoporotic fractures therapy: Current status and future perspectives

Bacterial extracellular vesicles: A position paper by the microbial vesicles task force of the Chinese society for extracellular vesicles

Extracellular vesicles in the treatment and prevention of osteoarthritis: can horses help us translate this therapy to humans?

Contact Info

Product

Resources

About